The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies |
| |
| Authors: | Sharon Elad DMD MSc Noam Yarom DMD Yehuda Zadik DMD MHA Michal Kuten-Shorrer DMD DMSc Stephen T Sonis DMD DMSc |
| |
| Institution: | 1. Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York;2. Sheba Medical Center, Tel Hashomer, Israel;3. Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel;4. Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts
Primary Endpoint Solutions, Waltham, Massachusetts |
| |
| Abstract: | Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy. |
| |
| Keywords: | cancer immune checkpoint inhibitors immunotherapy oral mucositis stomatitis targeted therapy toxicity ulcer |
|
|
